Company Information

  

Address: 100 BEAVER STREET
SUITE 201 
City: WALTHAM 
State: MA 
Zip Code: 02453 
Telephone: 781-996-5252 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle¬≠based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. Our MPPs are selectively¬≠sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus. We have applied the MPP technology to loteprednol etabonate, or LE, a corticosteroid designed for ocular applications, resulting in two lead product candidates.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/201810.39NA1.32
03/20181.69NA9.37
12/2017-6.11NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.19Total Liab/Total Assets0.23
Net Inc/Total Assets-0.36Total Liab/Inv Cap0.28
Net Inc/Inv Cap-0.44Total Liab/Comm Equity0.12
Pretax Inc/Net SalesNAInterest Coverage Ratio-40.42
Net Inc/Net SalesNACurr Debt/Equity0.07
Cash Flow/Net SalesNALTD/Equity0.13
SG&A/NetSalesNATotal Debt/Equity0.21
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio7.97
Inventory TurnoverNACurrent Ratio7.97
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) NA NA 0.00 NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 7.15 5.48 5.26 2.52
Operating Income -14.52 -11.14 -11.14 -9.53
Interest Exp 0.41 0.37 0.40 0.21
Pretax Income -14.62 -11.30 -11.29 -10.18
Other Income 0.31 0.21 0.25 -0.43
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -14.62 -11.30 -11.29 -10.18

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 91.21 100.53 114.57 122.05
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 91.94 101.41 115.21 122.94
Net Property, Plant & Equipment 1.25 1.08 0.79 0.62
Total Assets 95.59 104.99 116.13 123.69
Liabilities        
Accounts Payable 7.53 4.67 7.79 5.07
Debt in Current Liabilities 1.87 0.30 6.67 6.11
Total Current Liabilities 9.40 4.97 14.46 11.18
Long-Term Debt 18.10 19.75 11.99 13.63
Total Liabilities 27.50 24.72 26.45 24.83
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.03 0.02
Retained Earnings -160.29 -145.67 -134.37 -123.08
Treasury Stock NA NA NA NA
Total Stockholders' Equity 68.09 80.27 89.68 98.86
Total Liabilities and Stockholders' Equity 95.59 104.99 116.13 123.69

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -9.21 -12.71 -6.56 -9.33
Net Cash Provided by Investing Activities -0.17 -0.38 -0.26 -0.11
Net Cash Provided by Financing Activities 0.06 1.09 -0.64 105.12

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20150.04-16.68--
12/20160.00-33.17--
12/20170.00-42.21-6.11
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/188017,84372.56




Report Date : 9/24/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.